Probiotic characterization of Enterococcus faecium por1: Cloning, over expression of Enterocin-A and evaluation of antibacterial, anti-cancer properties

Ankaiah, Dasari; Esakkiraj, Palanichamy; Venkatesh, Perumal; Ayyanna, Repally; Arul, Venkatesan

doi:10.1016/j.jff.2017.09.034

Cited by 48 publications

(18 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Enterocin-A Effective antibacterial and anti-biofilm activity against food born as well as human bacterial pathogens (Ankaiah, Esakkiraj, Perumal, Ayyanna, & Venkatesan, 2017).…”

Section: Enterococcus Faeciummentioning

confidence: 99%

Advanced strategies for combating bacterial biofilms

Sharahi

Azimi

Shariati

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

Biofilms are communities of microorganisms that are formed on and attached to living or nonliving surfaces and are surrounded by an extracellular polymeric material. Biofilm formation enjoys several advantages over the pathogens in the colonization process of medical devices and patients' organs. Unlike planktonic cells, biofilms have high intrinsic resistance to antibiotics and sanitizers, and overcoming them is a significant problematic challenge in the medical and food industries. There are no approved treatments to specifically target biofilms. Thus, it is required to study and present innovative and effective methods to combat a bacterial biofilm. In this review, several strategies have been discussed for combating bacterial biofilms to improve healthcare, food safety, and industrial process.

show abstract

“…Enterocin-A Effective antibacterial and anti-biofilm activity against food born as well as human bacterial pathogens (Ankaiah, Esakkiraj, Perumal, Ayyanna, & Venkatesan, 2017).…”

Section: Enterococcus Faeciummentioning

confidence: 99%

Advanced strategies for combating bacterial biofilms

Sharahi

Azimi

Shariati

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

show abstract

“…Enterocin 12a inhibited the proliferation of all the tested cancer cell lines in a dose-dependent manner. Another enterocin i.e., enterocin A was earlier shown to reduce the viabilities of human cancer cell lines viz., HeLa, HT-29, AGS, and Caco-2 selectively by 60% at the maximum dose of 120 μg/ml [41]. However, as compared to enterocin-A, 12a appeared to be more potent as it reduced the viabilities of all the tested cell lines in the range 64-90% at a maximum dose of 5 μg/ml.…”

Section: Discussionmentioning

confidence: 90%

Anticancer and antimicrobial potential of enterocin 12a from Enterococcus faecium

et al. 2021

View full text Add to dashboard Cite

Background Increase in the number of infections caused by Gram-negative bacteria in neutropenic cancer patients has prompted the search for novel therapeutic agents having dual anticancer and antimicrobial properties. Bacteriocins are cationic proteins of prokaryotic origin that have emerged as one of the most promising alternative antimicrobial agents with applications as food preservatives and therapeutic agents. Apart from their antimicrobial activities, bacteriocins are also being explored for their anticancer potential. Results In this study, a broad-spectrum, cell membrane-permeabilizing enterocin with a molecular weight of 65 kDa was purified and characterized from the culture supernatant of vaginal Enterococcus faecium 12a. Enterocin 12a inhibited multidrug-resistant strains of various Gram-negative pathogens such as Salmonella enterica, Shigella flexneri, Vibrio cholerae, Escherichia coli and Gram-positive, Listeria monocytogenes, but had no activities against different strains of gut lactobacilli. The mass spectrometric analysis showed that the enterocin 12a shared partial homology with 4Fe-4S domain-containing redox protein of E. faecalis R712. Further, enterocin 12a selectively inhibited the proliferation of various human cancer cell lines in a dose-dependent manner but not that of normal human peripheral blood mononuclear cells. Enterocin 12a-treated cancer cells showed apoptosis-like morphological changes. Conclusion Enterocin 12a is a novel bacteriocin that has anticancer properties against human cell lines and negligible activity towards non-malignant cells. Therefore, it should be further evaluated for its anticancer potential in animal models.

show abstract

“…23 Ankaiah et.al studied the anti-cancer activity of enterocin-A against human colon, gastric (HT-29, Caco-2 and AGS) and cervical (HeLa) cancer cell lines and they found out that ent-A was able to induce apoptosis in HeLa cell line at a concentration of 120μg/ml, so that 53.93% of the cells had delayed apoptosis and 5.8% showed a primary apoptosis. 24 Fathizadeh et al in a review study investigated the role of bacteriocins as new potential therapeutic candidates in cancer therapy. They nd out that Evidence suggests that bacteriocins such as colcins, nisins, pediocins, pyocins, and bovocins are able to inhibit tumor growth at various stages by activating or inhibiting various cellular and molecular signaling pathways.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Apoptotic Activity of Protein Fusion Enterocin A- Pyocin R-Lactocin, Bacteriocins and Specific Ligand of Gastric Cancer Cell Line (AGS)

Jalalvand

Bashi

Raiszadeh

et al. 2021

Preprint

View full text Add to dashboard Cite

Conventional antimicrobial and anti-cancer treatments, including chemotherapy, surgery, radiation therapy, etc., have all been associated with antimicrobial resistance (AMR) and side effects on healthy cell damage. Recently, bacteriocins have emerged as a promising option in antimicrobial and anticancer therapies.In this study, EntA-PynR-Lac gene sequence was obtained using bioinformatics software. The designed fusion gene was synthesized and cloned into the pET22b expression vector and transferred to the engineered E. coli BL21 bacterium for expression of the recombinant protein. The three-dimensional structures and stability of the designed recombinant protein were evaluated. Confirmation and purification of the recombinant protein was performed by Western blotting and nickel column chromatography and determination of cell lethality of different concentrations of the recombinant protein against AGS cell line by MTT technique was conducted. Treatment of cells with different concentrations of protein to evaluate the apoptosis of AGS cells was performed by flow cytometry. The results showed that the percentage of cells treated with recombinant protein at a concentration of 80µg/ml with total apoptosis was 46.91% and increased by 36.25% compared to untreated cells. Due to the anti-apoptotic properties of fusion protein, it can be used to inhibit cancer cells as a therapeutic supplement and prevention.

show abstract

Probiotic characterization of Enterococcus faecium por1: Cloning, over expression of Enterocin-A and evaluation of antibacterial, anti-cancer properties

Cited by 48 publications

References 47 publications

Advanced strategies for combating bacterial biofilms

Advanced strategies for combating bacterial biofilms

Anticancer and antimicrobial potential of enterocin 12a from Enterococcus faecium

Evaluation of Apoptotic Activity of Protein Fusion Enterocin A- Pyocin R-Lactocin, Bacteriocins and Specific Ligand of Gastric Cancer Cell Line (AGS)

Contact Info

Product

Resources

About